on ReproNovo SA
ReproNovo Named Among "Fierce 15" Biotech Companies of 2026
ReproNovo, based in Lausanne and Copenhagen, has been recognized by Fierce Biotech as one of the "Fierce 15" biotechnology companies for 2026. This recognition highlights ReproNovo's innovative contributions to fertility and women’s health sectors. The company's main clinical programs target significant medical needs with therapies like RPN-001 for male infertility and RPN-002 for increasing pregnancy rates in women undergoing ART programs.
Fierce Biotech acknowledges the potential impact of ReproNovo’s therapies on global health challenges. ReproNovo’s commitment extends to advancing a global development strategy, with trials in the U.S., Europe, and China. The company aims to develop new solutions for infertility affecting both genders.
ReproNovo's CEO, Jean Marie Duvall, expresses gratitude for the recognition, underscoring the importance of their work in the biotech ecosystem. Recognition from Fierce Biotech, known for identifying promising biotechs, comes as the industry sees renewed investment and opportunities.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ReproNovo SA news